Vitamin D and Metabolic Syndrome: Is There a Link?

Current Pharmaceutical Design

Volumn 16, Issue 30, 2010, Pages 3417-3434

  Florentin, Matilda ^a,b   Elisaf, Moses S ^b   Mikhailidis, Dimitri P ^a   Liberopoulos, Evangelos N ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Blood pressure; Glucose; High density lipoprotein cholesterol; Insulin; Metabolic syndrome; Obesity; Triglycerides; Vitamin D

Indexed keywords

ALFACALCIDOL; ANGIOTENSIN; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; ERGOCALCIFEROL; GLUCOSE; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PARATHYROID HORMONE; PIOGLITAZONE; PLACEBO; RENIN; ROSIGLITAZONE; ROSUVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN D; VITAMIN D RECEPTOR;

AMERICAN INDIAN; ARTERIAL WALL THICKNESS; ATHEROGENESIS; BLOOD PRESSURE REGULATION; BODY COMPOSITION; BONE; CALCIUM ABSORPTION; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DAIRY PRODUCT; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FATTY ACID METABOLISM; FEEDBACK SYSTEM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID COMPOSITION; LYMPHOCYTE PROLIFERATION; METABOLIC SYNDROME X; OBESITY; PARATHYROID HORMONE BLOOD LEVEL; PODOCYTE; PRIORITY JOURNAL; RACE DIFFERENCE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; ULTRAVIOLET RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

EID: 78649810981     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563509     Document Type: Review

References (349)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
2. Vitamin D: A potential role in cardiovascular disease prevention. Available at http://www.medscape.com/viewarticle/713025. Last assessed August 10, 2010.
3. Ogunkolade BW, Boucher BJ, Prahl JM, et al. Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 2002; 51: 2294-300.
4. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15: 2579-85.
5. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003; 89: 552-72.
6. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997; 30: 150-6.
7. Kallay E, Bises G, Bajna E, et al. Colon-specific regulation of vitamin D hydroxylases--a possible approach for tumor prevention. Carcinogenesis 2005; 26: 1581-9.
8. van Driel M, Koedam M, Buurman CJ, et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 2006; 20: 2417-9.
9. Holick MF. Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications. In: Favus M, Ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington, DC: American Society for Bone and Mineral Research 2003; pp. 129-7.
10. MacDonald P. Molecular biology of the vitamin D receptor. In: Holick MF, Ed. Vitamin D: physiology, molecular biology, and clinical applications. Totowa, NJ: Humana Press 1999; pp. 109-28.
11. Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J 2005; 98: 1024-7.
12. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-76.
13. Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 2005; 35: 290-304.
14. Seibert E, Levin NW, Kuhlmann MK. Immunomodulating effects of vitamin D analogs in hemodialysis patients. Hemodial Int 2005; 9 Suppl 1: S25-9.
15. Simpson RU, Thomas GA, Arnold AJ. Identification of 1,25- dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem 1985; 260: 8882-91.
16. Bikle DD. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 1992; 13: 765-84.
17. Somjen D, Weisman Y, Kohen F, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111: 1666-71.
18. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-28.
19. Holick MF. Sunlight and vitamin D: both good for cardiovascular health. J Gen Intern Med 2002; 17: 733-5.
20. Pepe J, Romagnoli E, Nofroni I, et al. Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos Int 2005; 16: 805-12.
21. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998; 351: 805-6.
22. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev 2008; 13: 6-20.
23. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf) 2005; 62: 265-81.
24. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-37.
25. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92: 399-404.
26. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005; 6: 283-96.
27. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
28. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA 2002; 288: 2709-16.
29. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the metabolic syndrome and incidence of type 2 diabetes. Diabetes 2002; 51: 3120-7.
30. Liberopoulos EN, Elisaf MS. Diagnosis of the metabolic syndrome: which definition should we use? Hellenic J Cardiol 2005; 46: 258-62.
31. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
32. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80: 1689S-96S.
33. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003; 22: 142-6.
34. Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995; 333: 234-40.
35. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678S-88S.
36. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84: 18-28.
37. Holick MF. Calcium plus vitamin D and the risk of colorectal cancer. N Engl J Med 2006; 354: 2287-8.
38. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98: 451-9.
39. Penna G, Roncari A, Amuchastegui S, et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005; 106: 3490-7.
40. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842-56.
41. Kunes J, Tremblay J, Bellavance F, Hamet P. Influence of environmental temperature on the blood pressure of hypertensive patients in Montreal. Am J Hypertens 1991; 4: 422-6.
42. Woodhouse PR, Khaw KT, Plummer M. Seasonal variation of blood pressure and its relationship to ambient temperature in an elderly population. J Hypertens 1993; 11: 1267-74.
43. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med 1986; 105: 649-54.
44. Burgess ED, Hawkins RG, Watanabe M. Interaction of 1,25- dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens 1990; 3: 903-5.
45. Imaoka M, Morimoto S, Kitano S, Fukuo F, Ogihara T. Calcium metabolism in elderly hypertensive patients: possible participation of exaggerated sodium, calcium and phosphate excretion. Clin Exp Pharmacol Physiol 1991; 18: 631-41.
46. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac reninangiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-32.
47. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25- Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-38.
48. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521-4.
49. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calciumindependent and 1,25(OH)2D3-dependent regulation of the reninangiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008; 74: 170-9.
50. Carthy EP, Yamashita W, Hsu A, Ooi BS. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 1989; 13: 954-9.
51. Yuan W, Pan W, Kong J, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-30.
52. Park CW, Oh YS, Shin YS, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
53. Lind L, Wengle B, Wide L, Ljunghall S. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am J Hypertens 1989; 2: 20-5.
54. Kimura Y, Kawamura M, Owada M, et al. Effectiveness of 1,25- dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. Intern Med 1999; 38: 31-35.
55. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of reninangiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74: 1394-402.
56. Zehnder D, Bland R, Chana RS, et al. Synthesis of 1,25- dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 2002; 13: 621-9.
57. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008; 25: 320-5.
58. Wong MS, Delansorne R, Man RY, Vanhoutte PM. Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008; 295: H289-96.
59. Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008; 294: F1059-64.
60. Kahonen M, Nappi S, Jolma P, et al. Vascular influences of calcium supplementation and vitamin D-induced hypercalcemia in NaCl-hypertensive rats. J Cardiovasc Pharmacol 2003; 42: 319-28.
61. Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. The antiinflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol 2007; 103: 558-62.
62. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a proinflammatory profile. 1,25-Dihydroxyvitamin D(3) works as antiinflammatory. Diabetes Res Clin Pract 2007; 77: 47-57.
63. Hruska KA, Mathew S, Davies MR, Lund RJ. Connections between vascular calcification and progression of chronic kidney disease: therapeutic alternatives. Kidney Int Suppl 2005; S142-51.
64. Sambrook PN, Chen CJ, March L, et al. High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Miner Res 2006; 21: 549-55.
65. Wakasugi M, Noguchi T, Inoue M, et al. Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. Prostaglandins 1991; 42: 127-36.
66. Talmor Y, Bernheim J, Klein O, Green J, Rashid G. Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 in vitro. Eur J Clin Invest 2008; 38: 548-54.
67. Molostvov G, James S, Fletcher S, et al. Extracellular calciumsensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol 2007; 293: F946-55.
68. Wang D, An SJ, Wang WH, McGiff JC, Ferreri NR. CaR-mediated COX-2 expression in primary cultured mTAL cells. Am J Physiol Renal Physiol 2001; 281: F658-64.
69. Wang L, Manson JE, Buring JE, Lee IM, Sesso HD. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension 2008; 51: 1073-9.
70. Ishibashi K, Evans A, Shingu T, Bian K, Bukoski RD. Differential expression and effect of 1,25-dihydroxyvitamin D3 on myosin in arterial tree of rats. Am J Physiol 1995; 269: C443-50.
71. Shan J, Resnick LM, Lewanczuk RZ, Karpinski E, Li B, Pang PK. 1,25-dihydroxyvitamin D as a cardiovascular hormone. Effects on calcium current and cytosolic free calcium in vascular smooth muscle cells. Am J Hypertens 1993; 6: 983-8.
72. Roca-Cusachs A, DiPette DJ, Carson J, Graham GA, Holland OB. Systemic and regional hemodynamic effects of 1,25- dihydroxyvitamin D3 administration. J Hypertens 1992; 10: 939-47.
73. Bukoski RD, DeWan P, McCarron DA. 1,25 (OH)2 vitamin D3 modifies growth and contractile function of vascular smooth muscle of spontaneously hypertensive rats. Am J Hypertens 1989; 2: 553-6.
74. Bukoski RD, Wang DB, Wagman DW. Injection of 1,25-(OH)2 vitamin D3 enhances resistance artery contractile properties. Hypertension 1990; 16: 523-31.
75. Hatton DC, Xue H, DeMerritt JA, McCarron DA. 1,25(OH)2 vitamin D3-induced alterations in vascular reactivity in the spontaneously hypertensive rat. Am J Med Sci 1994; 307 Suppl 1: S154-8.
76. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-20.
77. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-33.
78. Hariharan S, Hong SY, Hsu A, MacCarthy EP, Gartside PS, Ool BS. Effect of 1,25-dihydroxyvitamin D3 on mesangial cell proliferation. J Lab Clin Med 1991; 117: 423-9.
79. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-8.
80. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 2008; 6: 77-83.
81. Snijder MB, Lips P, Seidell JC, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a populationbased study in older men and women. J Intern Med 2007; 261: 558-65.
82. Hulter HN, Melby JC, Peterson JC, Cooke CR. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1986; 2: 360-70.
83. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and metaanalysis. J Clin Endocrinol Metab 2007; 92: 2017-29.
84. Muray S, Parisi E, Cardus A, Craver L, Fernandez E. Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. J Hypertens 2003; 21: 2069-75.
85. Lee S, Clark SA, Gill RK, Christakos S. 1,25-Dihydroxyvitamin D3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology 1994; 134: 1602-10.
86. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab 2007; 92: 3517-22.
87. Carlin AM, Yager KM, Rao DS. Vitamin D depletion impairs hypertension resolution after Roux-en-Y gastric bypass. Am J Surg 2008; 195: 349-52.
88. Armbrecht HJ, Hodam TL, Boltz MA, Kumar VB. Capacity of a low calcium diet to induce the renal vitamin D 1a-hydroxylase is decreased in adult rats. Biochem Biophys Res Commun 1999; 255: 731-4.
89. Dobnig H, Pfeifer M, Begerow B, Suppan K. Calcium, not vitamin D decreases blood pressure effectively in elderly subjects with low vitamin D levels; a randomized, double-blind, multicenter study. Abstracts of Annual Meeting of American Endocrine Society. San Diego, CA 2005.
90. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007; 20: 713-9.
91. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007; 167: 1159-65.
92. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 1995; 8: 894-901.
93. Rueda S, Fernandez-Fernandez C, Romero F, Martinez de Osaba J, Vidal J. Vitamin D, PTH, and the metabolic syndrome in severely obese subjects. Obes Surg 2008; 18: 151-4.
94. Scragg R, Holdaway I, Jackson R, Lim T. Plasma 25- hydroxyvitamin D3 and its relation to physical activity and other heart disease risk factors in the general population. Ann Epidemiol 1992; 2: 697-703.
95. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxycholecalciferol concentration in newly detected hypertension. Am J Hypertens 1995; 8: 429-32.
96. Scragg R, Khaw KT, Murphy S. Life-style factors associated with winter serum 25-hydroxyvitamin D levels in elderly adults. Age Ageing 1995; 24: 271-5.
97. Reichel H, Liebethal R, Hense HW, Schmidt-Gayk H, Ritz E. Disturbed calcium metabolism in subjects with elevated diastolic blood pressure. Clin Investig 1992; 70: 748-51.
98. Reis JP, von Muhlen D, Kritz-Silverstein D, Wingard DL, Barrett-Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007; 30: 1549-55.
99. Brickman AS, Nyby MD, von Hungen K, Eggena P, Tuck ML. Calcitropic hormones, platelet calcium, and blood pressure in essential hypertension. Hypertension 1990; 16: 515-22.
100. Kokot F, Schmidt-Gayk H, Wiecek A, Mleczko Z, Bracel B. Influence of ultraviolet irradiation on plasma vitamin D and calcitonin levels in humans. Kidney Int Suppl 1989; 27: S143-6.
101. Argiles A, Lorho R, Servel MF, Couret I, Chong G, Mourad G. Blood pressure is correlated with vitamin D(3) serum levels in dialysis patients. Blood Purif 2002; 20: 370-5.
102. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2008; 87: 136-41.
103. Hintzpeter B, Mensink GB, Thierfelder W, Muller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur J Clin Nutr 2008; 62: 1079-89.
104. Hypponen E, Boucher BJ, Berry DJ, Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a crosssectional study in the 1958 British Birth Cohort. Diabetes 2008; 57: 298-305.
105. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338: 777-83.
106. Kokot F, Pietrek J, Srokowska S, et al. 25-hydroxyvitamin D in patients with essential hypertension. Clin Nephrol 1981; 16: 188-92.
107. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008; 57: 2619-25.
108. Duprez D, de Buyzere M, de Backer T, Clement D. Relationship between vitamin D3 and the peripheral circulation in moderate arterial primary hypertension. Blood Press 1994; 3: 389-93.
109. Pasco JA, Henry MJ, Nicholson GC, Brennan SL, Kotowicz MA. Behavioural and physical characteristics associated with vitamin D status in women. Bone 2009; 44: 1085-91.
110. Kulah E, Dursun A, Aktunc E, Acikgoz S, Aydin M, Can M. Effects of angiotensin-converting enzyme gene polymorphism and serum vitamin D levels on ambulatory blood pressure measurement and left ventricular mass in Turkish hypertensive population. Blood Press Monit 2007; 12: 207-13.
111. Gannage-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol 2009; 160: 965-71.
112. Smotkin-Tangorra M, Purushothaman R, Gupta A, Nejati G, Anhalt H, Ten S. Prevalence of vitamin D insufficiency in obese children and adolescents. J Pediatr Endocrinol Metab 2007; 20: 817-23.
113. Landin-Wilhelmsen K, Wilhelmsen L, Wilske J, et al. Sunlight increases serum 25(OH) vitamin D concentration whereas 1,25(OH)2D3 is unaffected. Results from a general population study in Goteborg, Sweden (The WHO MONICA Project). Eur J Clin Nutr 1995; 49: 400-7.
114. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25- hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49: 1063-9.
115. Almirall J, Vaqueiro M, Bare ML, Anton E. Association of low serum 25-hydroxyvitamin D levels and high arterial blood pressure in the elderly. Nephrol Dial Transplant 2010; 25: 503-9.
116. Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 2009; 6: 621-30.
117. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008; 52: 828-32.
118. Forman JP, Bischoff-Ferrari HA, Willett WC, Stampfer MJ, Curhan GC. Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension 2005; 46: 676-82.
119. Jorde R, Bonaa KH. Calcium from dairy products, vitamin D intake, and blood pressure: the Tromso Study. Am J Clin Nutr 2000; 71: 1530-5.
120. Sowers MR, Wallace RB, Lemke JH. The association of intakes of vitamin D and calcium with blood pressure among women. Am J Clin Nutr 1985; 42: 135-42.
121. Joffres MR, Reed DM, Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am J Clin Nutr 1987; 45: 469-75.
122. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension 1997; 30: 1289-94.
123. Young EW, McCarron DA, Morris CD. Calcium regulating hormones in essential hypertension. Importance of gender. Am J Hypertens 1990; 3: 161S-6S.
124. Young EW, Morris CD, Holcomb S, McMillan G, McCarron DA. Regulation of parathyroid hormone and vitamin D in essential hypertension. Am J Hypertens 1995; 8: 957-64.
125. St John A, Dick I, Hoad K, Retallack R, Welborn T, Prince R. Relationship between calcitrophic hormones and blood pressure in elderly subjects. Eur J Endocrinol 1994; 130: 446-50.
126. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86: 1633-7.
127. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet 1998; 352: 709-10.
128. Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009; 26: 19-27.
129. Orwoll ES, Oviatt S. Relationship of mineral metabolism and longterm calcium and cholecalciferol supplementation to blood pressure in normotensive men. Am J Clin Nutr 1990; 52: 717-21.
130. Major GC, Alarie F, Dore J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr 2007; 85: 54-9.
131. Pan WH, Wang CY, Li LA, Kao LS, Yeh SH. No significant effect of calcium and vitamin D supplementation on blood pressure and calcium metabolism in elderly Chinese. Chin J Physiol 1993; 36: 85-94.
132. Margolis KL, Ray RM, Van Horn L, et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension 2008; 52: 847-55.
133. Daly RM, Nowson CA. Long-term effect of calcium-vitamin D(3) fortified milk on blood pressure and serum lipid concentrations in healthy older men. Eur J Clin Nutr 2009; 63: 993-1000.
134. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83: 754-9.
135. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009; 89: 1321-7.
136. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669-83.
137. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure' a systematic review and meta-analysis. J Hypertens 2009; 27: 1948-54.
138. Lind L, Wengle B, Wide L, Sorensen OH, Ljunghall S. Hypertension in primary hyperparathyroidism-reduction of blood pressure by long-term treatment with vitamin D (alphacalcidol). A doubleblind, placebo-controlled study. Am J Hypertens 1988; 1: 397-402.
139. Qiao G, Kong J, Uskokovic M, Li YC. Analogs of 1alpha,25- dihydroxyvitamin D(3) as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 2005; 96: 59-66.
140. Kawahara M, Iwasaki Y, Sakaguchi K, et al. Predominant role of 25OHD in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. Life Sci 2008; 82: 677-83.
141. Piovesan A, Molineri N, Casasso F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999; 50: 321-8.
142. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6.
143. Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997; 82: 106-12.
144. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
145. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-9.
146. Lind L, Pollare T, Hvarfner A, Lithell H, Sorensen OH, Ljunghall S. Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res 1989; 11: 141-7.
147. Lind L, Wengle B, Ljunghall S. Blood pressure is lowered by vitamin D (alphacalcidol) during long-term treatment of patients with intermittent hypercalcaemia. A double-blind, placebo-controlled study. Acta Med Scand 1987; 222: 423-7.
148. Lind L, Wengle B, Lithell H, Ljunghall S. Plasma ionized calcium and cardiovascular risk factors in mild primary hyperparathyroidism: effects of long-term treatment with active vitamin D (alphacalcidol). J Intern Med 1992; 231: 427-32.
149. Lind L, Lithell H, Skarfors E, Wide L, Ljunghall S. Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance. Acta Med Scand 1988; 223: 211-7
150. Mak RH. Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients. Pediatr Nephrol 1992; 6: 345-8.
151. Jespersen B, Randlov A, Abrahamsen J, Fogh-Andersen N, Olsen NV, Kanstrup IL. Acute cardiovascular effect of 1,25- dihydroxycholecalciferol in essential hypertension. Am J Hypertens 1998; 11: 659-66.
152. Fliser D, Stefanski A, Franek E, Fode P, Gudarzi A, Ritz E. No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects. Eur J Clin Invest 1997; 27: 629-33.
153. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis 2008; 51: 724-31.
154. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-55.
155. Bourlon PM, Billaudel B, Faure-Dussert A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol 1999; 160: 87-95.
156. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003; 17: 509-11.
157. Johnson JA, Grande JP, Roche PC, Kumar R. Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol 1994; 267: E356-60.
158. Maestro B, Davila N, Carranza MC, Calle C. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003; 84: 223-30.
159. Maestro B, Molero S, Bajo S, Davila N, Calle C. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem Funct 2002; 20: 227-32.
160. Bland R, Markovic D, Hills CE, et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 2004; 89-90: 121-5.
161. Hitman GA, Mannan N, McDermott MF, et al. Vitamin D receptor gene polymorphisms influence insulin secretion in Bangladeshi Asians. Diabetes 1998; 47: 688-90.
162. Ortlepp JR, Metrikat J, Albrecht M, von Korff A, Hanrath P, Hoffmann R. The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. Diabet Med 2003; 20: 451-4.
163. Oh JY, Barrett-Connor E. Association between vitamin D receptor polymorphism and type 2 diabetes or metabolic syndrome in community-dwelling older adults: the Rancho Bernardo Study. Metabolism 2002; 51: 356-9.
164. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 2008; 10: 185-97.
165. Kadowaki S, Norman AW. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest 1984; 73: 759-66.
166. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980; 209: 823-5.
167. Tanaka Y, Seino Y, Ishida M, et al. Effect of vitamin D3 on the pancreatic secretion of insulin and somatostatin. Acta Endocrinol (Copenh) 1984; 105: 528-33.
168. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986; 119: 84-90.
169. Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 1983; 113: 1511-8.
170. Clark SA, Stumpf WE, Sar M. Effect of 1,25 dihydroxyvitamin D3 on insulin secretion. Diabetes 1981; 30: 382-6.
171. Gedik O, Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia 1986; 29: 142-5.
172. Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? Br J Nutr 1998; 79: 315-27.
173. Baynes KC, Boucher BJ, Feskens EJ, Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997; 40: 344-7.
174. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79: 820-5.
175. Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 2003; 57: 258-61.
176. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 1995; 38: 1239-45.
177. Orwoll E, Riddle M, Prince M. Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1994; 59: 1083-7.
178. Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T. Effect of 1 alpha (OH)-vitamin D3 on insulin secretion in diabetes mellitus. Bone Miner 1986; 1: 187-92.
179. Tai K, Need AG, Horowitz M, Chapman IM. Vitamin D, glucose, insulin, and insulin sensitivity. Nutrition 2008; 24: 279-85.
180. Nyomba BL, Auwerx J, Bormans V, et al. Pancreatic secretion in man with subclinical vitamin D deficiency. Diabetologia 1986; 29: 34-8.
181. Colas C, Garabedian M, Fontbonne A, et al. Insulin secretion and plasma 1,25-(OH)2D after UV-B irradiation in healthy adults. Horm Metab Res 1989; 21: 154-5.
182. Bourlon PM, Faure-Dussert A, Billaudel B. The de novo synthesis of numerous proteins is decreased during vitamin D3 deficiency and is gradually restored by 1, 25-dihydroxyvitamin D3 repletion in the islets of langerhans of rats. J Endocrinol 1999; 162: 101-9.
183. Kajikawa M, Ishida H, Fujimoto S, et al. An insulinotropic effect of vitamin D analog with increasing intracellular Ca2+ concentration in pancreatic beta-cells through nongenomic signal transduction. Endocrinology 1999; 140: 4706-12.
184. Sooy K, Schermerhorn T, Noda M, et al. Calbindin-D(28k) controls [Ca(2+)](i) and insulin release. Evidence obtained from calbindind(28k) knockout mice and beta cell lines. J Biol Chem 1999; 274: 34343-9.
185. Milner RD, Hales CN. The role of calcium and magnesium in insulin secretion from rabbit pancreas studied in vitro. Diabetologia 1967; 3: 47-9.
186. Sergeev IN, Rhoten WB. 1,25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. Endocrinology 1995; 136: 2852-61.
187. Yasuda K, Hurukawa Y, Okuyama M, Kikuchi M, Yoshinaga K. Glucose tolerance and insulin secretion in patients with parathyroid disorders. Effect of serum calcium on insulin release. N Engl J Med 1975; 292: 501-4.
188. Gedik O, Zileli MS. Effects of hypocalcemia and theophylline on glucose tolerance and insulin release in human beings. Diabetes 1977; 26: 813-9.
189. Hochberg Z, Borochowitz Z, Benderli A, et al. Does 1,25- dihydroxyvitamin D participate in the regulation of hormone release from endocrine glands? J Clin Endocrinol Metab 1985; 60: 57-61.
190. Fujita T, Sakagami Y, Tomita T, Okamoto Y, Oku H. Insulin secretion after oral calcium load. Endocrinol Jpn 1978; 25: 645-8.
191. Beaulieu C, Kestekian R, Havrankova J, Gascon-Barre M. Calcium is essential in normalizing intolerance to glucose that accompanies vitamin D depletion in vivo. Diabetes 1993; 42: 35-43.
192. Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25- dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 2000; 47: 383-91.
193. Luquet S, Gaudel C, Holst D, et al. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim Biophys Acta 2005; 1740: 313-7.
194. Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol 2005; 349: 248-60.
195. Zhou QG, Hou FF, Guo ZJ, Liang M, Wang GB, Zhang X. 1,25- Dihydroxyvitamin D improved the free fatty-acid-induced insulin resistance in cultured C2C12 cells. Diabetes Metab Res Rev 2008; 24: 459-64.
196. Ojuka EO. Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc Nutr Soc 2004; 63: 275-8.
197. Wright DC, Hucker KA, Holloszy JO, Han DH. Ca2+ and AMPK both mediate stimulation of glucose transport by muscle contractions. Diabetes 2004; 53: 330-5.
198. Williams PF, Caterson ID, Cooney GJ, Zilkens RR, Turtle JR. High affinity insulin binding and insulin receptor-effector coupling: modulation by Ca2+. Cell Calcium 1990; 11: 547-56.
199. Draznin B, Sussman K, Kao M, Lewis D, Sherman N. The existence of an optimal range of cytosolic free calcium for insulinstimulated glucose transport in rat adipocytes. J Biol Chem 1987; 262: 14385-8.
200. Segal S, Lloyd S, Sherman N, Sussman K, Draznin B. Postprandial changes in cytosolic free calcium and glucose uptake in adipocytes in obesity and non-insulin-dependent diabetes mellitus. Horm Res 1990; 34: 39-44.
201. Ohno Y, Suzuki H, Yamakawa H, Nakamura M, Otsuka K, Saruta T. Impaired insulin sensitivity in young, lean normotensive offspring of essential hypertensives: possible role of disturbed calcium metabolism. J Hypertens 1993; 11: 421-6.
202. Zemel MB. Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Mol Cell Biochem 1998; 188: 129-36.
203. Draznin B, Lewis D, Houlder N, et al. Mechanism of insulin resistance induced by sustained levels of cytosolic free calcium in rat adipocytes. Endocrinology 1989; 125: 2341-9.
204. Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest 1988; 82: 1848-52.
205. Byyny RL, LoVerde M, Lloyd S, Mitchell W, Draznin B. Cytosolic calcium and insulin resistance in elderly patients with essential hypertension. Am J Hypertens 1992; 5: 459-64.
206. Reusch JE, Begum N, Sussman KE, Draznin B. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology 1991; 129: 3269-73.
207. Plehwe WE, Williams PF, Caterson ID, Harrison LC, Turtle JR. Calcium-dependence of insulin receptor phosphorylation. Biochem J 1983; 214: 361-6.
208. Zemel MB, Shi H, Greer B, Dirienzo D, Zemel PC. Regulation of adiposity by dietary calcium. FASEB J 2000; 14: 1132-8.
209. McCarty MF, Thomas CA. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses 2003; 61: 535-42.
210. Barbagallo M, Shan J, Pang PK, Resnick LM. Glucose-induced alterations of cytosolic free calcium in cultured rat tail artery vascular smooth muscle cells. J Clin Invest 1995; 95: 763-7.
211. Barbagallo M, Gupta RK, Resnick LM. Cellular ions in NIDDM: relation of calcium to hyperglycemia and cardiac mass. Diabetes Care 1996; 19: 1393-8.
212. Levy J. Abnormal cell calcium homeostasis in type 2 diabetes mellitus: a new look on old disease. Endocrine 1999; 10: 1-6.
213. Chiu KC, Chuang LM, Lee NP, et al. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 2000; 49: 1501-5.
214. Ni Z, Smogorzewski M, Massry SG. Effects of parathyroid hormone on cytosolic calcium of rat adipocytes. Endocrinology 1994; 135: 1837-44.
215. Baczynski R, Massry SG, Magott M, el-Belbessi S, Kohan R, Brautbar N. Effect of parathyroid hormone on energy metabolism of skeletal muscle. Kidney Int 1985; 28: 722-7.
216. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third national health and nutrition examination survey. Diabetes Care 2004; 27: 2813-8.
217. Procopio M, Borretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest 2003; 26: 1136-42.
218. Procopio M, Magro G, Cesario F, et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002; 19: 958-61.
219. Taylor WH. The prevalence of diabetes mellitus in patients with primary hyperparathyroidism and among their relatives. Diabet Med 1991; 8: 683-7.
220. Kautzky-Willer A, Pacini G, Niederle B, Schernthaner G, Prager R. Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery. Clin Endocrinol (Oxf) 1992; 37: 147-55.
221. Prager R, Kovarik J, Schernthaner G, Woloszczuk W, Willvonseder R. Peripheral insulin resistance in primary hyperparathyroidism. Metabolism 1983; 32: 800-5.
222. Kumar S, Olukoga AO, Gordon C, et al. Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1994; 40: 47-53.
223. Richards ML, Thompson NW. Diabetes mellitus with hyperparathyroidism: another indication for parathyroidectomy? Surgery 1999; 126: 1160-6.
224. Chen SM, Young TK, Ho LT. Effects of parathyroid hormone infusion on glucose tolerance and glucose-stimulated insulin secretion in normal and uremic rats. Diabetes Res Clin Pract 1998; 41: 85-94.
225. Fliser D, Franek E, Fode P, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997; 12: 933-8.
226. Mak RH. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 1992; 41: 1049-54.
227. Iyengar S, Hamman RF, Marshall JA, Majumder PP, Ferrell RE. On the role of vitamin D binding globulin in glucose homeostasis: results from the San Luis Valley Diabetes Study. Genet Epidemiol 1989; 6: 691-8.
228. Bonakdaran S, Varasteh AR. Correlation between serum 25 hydroxy vitamin D3 and laboratory risk markers of cardiovascular diseases in type 2 diabetic patients. Saudi Med J 2009; 30: 509-14.
229. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005; 28: 1228-30.
230. Cigolini M, Iagulli MP, Miconi V, Galiotto M, Lombardi S, Targher G. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 2006; 29: 722-4.
231. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract 1995; 27: 181-8.
232. Christiansen C, Christensen MS, McNair P, Nielsen B, Madsbad S. Vitamin D metabolites in diabetic patients: decreased serum concentration of 24,25-dihydroxyvitamin D. Scand J Clin Lab Invest 1982; 42: 487-91.
233. Stepan J, Wilczek H, Justova V, et al. Plasma 25- hydroxycholecalciferol in oral sulfonylurea treated diabetes mellitus. Horm Metab Res 1982; 14: 98-100.
234. Nyomba BL, Bouillon R, Bidingija M, Kandjingu K, De Moor P. Vitamin D metabolites and their binding protein in adult diabetic patients. Diabetes 1986; 35: 911-5.
235. Pietschmann P, Schernthaner G, Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia 1988; 31: 892-5.
236. Aksoy H, Akcay F, Kurtul N, Baykal O, Avci B. Serum 1,25 dihydroxy vitamin D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. Clin Biochem 2000; 33: 47-51.
237. Isaia G, Giorgino R, Adami S. High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 2001; 24: 1496.
238. Hypponen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care 2006; 29: 2244-6.
239. Ishii H, Suzuki H, Baba T, Nakamura K, Watanabe T. Seasonal variation of glycemic control in type 2 diabetic patients. Diabetes Care 2001; 24: 1503.
240. Kumar S, Davies M, Zakaria Y, et al. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 1994; 70: 440-3.
241. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007; 30: 980-6.
242. Avenell A, Cook JA, MacLennan GS, McPherson GC. Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing 2009; 38: 606-9.
243. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-72.
244. Pereira MA, Jacobs DR, Jr., Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. JAMA 2002; 287: 2081-9.
245. Tai K, Need AG, Horowitz M, Chapman IM. Glucose tolerance and vitamin D: effects of treating vitamin D deficiency. Nutrition 2008; 24: 950-6.
246. Kaneto H, Fujii J, Seo HG, et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes 1995; 44: 733-8.
247. Delaney CA, Pavlovic D, Hoorens A, Pipeleers DG, Eizirik DL. Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells. Endocrinology 1997; 138: 2610-4.
248. Riachy R, Vandewalle B, Kerr Conte J, et al. 1,25- dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20. Endocrinology 2002; 143: 4809-19.
249. Gysemans CA, Cardozo AK, Callewaert H, et al. 1,25- Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005; 146: 1956-64.
250. van Etten E, Mathieu C. Immunoregulation by 1,25- dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93-101.
251. D'Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NFkappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101: 252-62.
252. Rabinovitch A, Suarez-Pinzon WL, Sooy K, Strynadka K, Christakos S. Expression of calbindin-D(28k) in a pancreatic islet betacell line protects against cytokine-induced apoptosis and necrosis. Endocrinology 2001; 142: 3649-55.
253. Kadowaki S, Norman AW. Pancreatic vitamin D-dependent calcium binding protein: biochemical properties and response to vitamin D. Arch Biochem Biophys 1984; 233: 228-36.
254. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89: 447-52.
255. Christakos S, Barletta F, Huening M, et al. Vitamin D target proteins: function and regulation. J Cell Biochem 2003; 88: 238-44.
256. Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95: 787-96.
257. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006; 29: 650-6.
258. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286: H1597-602.
259. Scopinaro N, Gianetta E, Civalleri D, Bonalumi U, Bachi V. Biliopancreatic bypass for obesity: II. Initial experience in man. Br J Surg 1979; 66: 618-20.
260. Slater GH, Ren CJ, Siegel N, et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastrointest Surg 2004; 8: 48-55.
261. Newbury L, Dolan K, Hatzifotis M, Low N, Fielding G. Calcium and vitamin D depletion and elevated parathyroid hormone following biliopancreatic diversion. Obes Surg 2003; 13: 893-5.
262. Parikh SJ, Edelman M, Uwaifo GI, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 2004; 89: 1196-9.
263. Greco AV, Mingrone G, Giancaterini A, et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002; 51: 144-51.
264. Mingrone G, Rosa G, Greco AV, et al. Intramyocitic lipid accumulation and SREBP-1c expression are related to insulin resistance and cardiovascular risk in morbid obesity. Atherosclerosis 2003; 170: 155-61.
265. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997; 100: 1166-73.
266. Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008; 19: 666-71.
267. Mattila C, Knekt P, Mannisto S, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 2007; 30: 2569-70.
268. de Boer IH, Tinker LF, Connelly S, et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008; 31: 701-7.
269. Carbone LD, Rosenberg EW, Tolley EA, et al. 25-Hydroxyvitamin D, cholesterol, and ultraviolet irradiation. Metabolism 2008; 57: 741-8.
270. Auwerx J, Bouillon R, Kesteloot H. Relation between 25- hydroxyvitamin D3, apolipoprotein A-I, and high density lipoprotein cholesterol. Arterioscler Thromb 1992; 12: 671-4.
271. John WG, Noonan K, Mannan N, Boucher BJ. Hypovitaminosis D is associated with reductions in serum apolipoprotein A-I but not with fasting lipids in British Bangladeshis. Am J Clin Nutr 2005; 82: 517-22.
272. Maki KC, Rubin MR, Wong LG, McManus JF, Jensen CD, Marshall JW, Lawless A. Serum 25-hydroxyvitamin D is independently associated with high-density lipoprotein cholesterol and the metabolic syndrome in men and women. J Clin Lipidol 2009; 3: 289-96.
273. Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA, Vazquez C, Escobar-Morreale HF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin Nutr 2007; 26: 573-80.
274. Reis JP, von Muhlen D, Miller ER, 3rd. Relation of 25- hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur J Endocrinol 2008; 159: 41-8.
275. Liu E, Meigs JB, Pittas AG, et al. Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 2009; 139: 329-34.
276. Denke MA, Fox MM, Schulte MC. Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men. J Nutr 1993; 123: 1047-53.
277. Reid IR. Effects of calcium supplementation on circulating lipids: potential pharmacoeconomic implications. Drugs Aging 2004; 21: 7-17.
278. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990; 31: 1149-72.
279. Vaskonen T. Dietary minerals and modification of cardiovascular risk factors. J Nutr Biochem 2003; 14: 492-506.
280. Van der Meer R, Welberg JW, Kuipers F, et al. Effects of supplemental dietary calcium on the intestinal association of calcium, phosphate, and bile acids. Gastroenterology 1990; 99: 1653-9.
281. Cho HJ, Kang HC, Choi SA, Ju YC, Lee HS, Park HJ. The possible role of Ca2+ on the activation of microsomal triglyceride transfer protein in rat hepatocytes. Biol Pharm Bull 2005; 28: 1418-23.
282. Melanson EL, Donahoo WT, Dong F, Ida T, Zemel MB. Effect of low- and high-calcium dairy-based diets on macronutrient oxidation in humans. Obes Res 2005; 13: 2102-12.
283. Melanson EL, Sharp TA, Schneider J, Donahoo WT, Grunwald GK, Hill JO. Relation between calcium intake and fat oxidation in adult humans. Int J Obes Relat Metab Disord 2003; 27: 196-203.
284. Andersen R, Brot C, Mejborn H, et al. Vitamin D supplementation does not affect serum lipids and lipoproteins in Pakistani immigrants. Eur J Clin Nutr 2009; 63: 1150-3.
285. Lind L, Wengle B, Lithell H, Ljunghall S. No major metabolic alterations accompany the hypotensive effect of active vitamin D. Ups J Med Sci 1991; 96: 199-204.
286. Heikkinen AM, Tuppurainen MT, Niskanen L, Komulainen M, Penttila I, Saarikoski S. Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. Eur J Endocrinol 1997; 137: 495-502.
287. Tuppurainen M, Heikkinen AM, Penttila I, Saarikoski S. Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3. Maturitas 1995; 22: 55-61.
288. Karanja N, Morris CD, Rufolo P, Snyder G, Illingworth DR, McCarron DA. Impact of increasing calcium in the diet on nutrientconsumption, plasma lipids, and lipoproteins in humans. Am J Clin Nutr 1994; 59: 900-7.
289. Khajehdehi P. Effect of vitamins on the lipid profile of patients on regular hemodialysis. Scand J Urol Nephrol 2000; 34: 62-6.
290. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998; 53: 1353-7.
291. Lim PS, Hung TS, Yeh CH, Yu MH. Effects of treatment of secondary hyperparathyroidism on the lipid profile in patients on hemodialysis. Blood Purif 1998; 16: 22-9.
292. Yeksan M, Turk S, Polat M, Cigli A, Erdogan Y. Effects of 1,25 (OH)2D3 treatment on lipid levels in uremic hemodialysis patients. Int J Artif Organs 1992; 15: 704-7.
293. Khajehdehi P, Taheri S. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysispatients: its safety in a combination with oral calcium carbonate. J Ren Nutr 2003; 13: 78-83.
294. Lin SH, Lin YF, Lu KC, et al. Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin Sci (Lond) 1994; 87: 533-8.
295. Arunabh S, Pollack S, Yeh J, Aloia JF. Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 2003; 88: 157-61.
296. Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S. Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 1985; 76: 370-3.
297. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-3.
298. Looker AC. Body fat and vitamin D status in black versus white women. J Clin Endocrinol Metab 2005; 90: 635-40.
299. McGill AT, Stewart JM, Lithander FE, Strik CM, Poppitt SD. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J 2008; 7: 4.
300. Harris SS, Dawson-Hughes B. Reduced sun exposure does not explain the inverse association of 25-hydroxyvitamin D with percent body fat in older adults. J Clin Endocrinol Metab 2007; 92: 3155-7.
301. Yanoff LB, Parikh SJ, Spitalnik A, et al. The prevalence of hypovitaminosis D and secondary hyperparathyroidism in obese Black Americans. Clin Endocrinol (Oxf) 2006; 64: 523-9.
302. Aasheim ET, Hofso D, Hjelmesaeth J, Birkeland KI, Bohmer T. Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr 2008; 87: 362-9.
303. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952-67.
304. Caan B, Neuhouser M, Aragaki A, et al. Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain. Arch Intern Med 2007; 167: 893-902.
305. Li J, Byrne ME, Chang E, et al. 1alpha,25-Dihydroxyvitamin D hydroxylase in adipocytes. J Steroid Biochem Mol Biol 2008; 112: 122-6.
306. McCarty MF. Poor vitamin D status may contribute to high risk for insulin resistance, obesity, and cardiovascular disease in Asian Indians. Med Hypotheses 2009; 72: 647-51.
307. Tahrani AA, Ball A, Shepherd L, Rahim A, Jones AF, Bates A. The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK. Int J Clin Pract 2010; 64: 351-5.
308. Reis JP, Michos ED, von Muhlen D, Miller ER, 3rd. Differences in vitamin D status as a possible contributor to the racial disparity in peripheral arterial disease. Am J Clin Nutr 2008; 88: 1469-77.
309. Lee DM, Rutter MK, O'Neill TW, et al. Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men. Eur J Endocrinol 2009; 161: 947-54.
310. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005; 28: 2926-32.
311. Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi F. Dairy consumption is inversely associated with the prevalence of the metabolic syndrome in Tehranian adults. Am J Clin Nutr 2005; 82: 523-30.
312. Mennen LI, Lafay L, Feskens EJM, Novak M, Lepinay P, Balkau B. Possible protective effect of bread and dairy products on the risk of the metabolic syndrome. Nutr Res 2000; 20: 335-47.
313. Saggese G, Federico G, Balestri M, Toniolo A. Calcitriol inhibits the PHA-induced production of IL-2 and IFN-gamma and the proliferation of human peripheral blood leukocytes while enhancing the surface expression of HLA class II molecules. J Endocrinol Invest 1989; 12: 329-35.
314. Jouni ZE, Winzerling JJ, McNamara DJ. 1,25-Dihydroxyvitamin D3-induced HL-60 macrophages: regulation of cholesterol and LDL metabolism. Atherosclerosis 1995; 117: 125-38.
315. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78: 539-52.
316. van Kimmenade RR, Januzzi JL, Jr. The evolution of the natriuretic peptides - Current applications in human and animal medicine. J Vet Cardiol 2009; 11 Suppl 1: S9-21.
317. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 2009; 9: 182-94.
318. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006; 186: 20-8.
319. Sochorova K, Budinsky V, Rozkova D, et al. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol 2009; 133: 69-77.
320. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004; 279: 35798-802.
321. Urakawa H, Katsuki A, Sumida Y, et al. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab 2003; 88: 4673-6.
322. Perticone F, Ceravolo R, Candigliota M, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001; 50: 159-65.
323. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 2009; 94: 4023-30.
324. Wiseman H. Vitamin D is a membrane antioxidant. Ability to inhibit iron-dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action. FEBS Lett 1993; 326: 285-8.
325. Sardar S, Chakraborty A, Chatterjee M. Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague--Dawley rats. Int J Vitam Nutr Res 1996; 66: 39-45.
326. Menendez C, Lage M, Peino R, et al. Retinoic acid and vitamin D(3) powerfully inhibit in vitro leptin secretion by human adipose tissue. J Endocrinol 2001; 170: 425-31.
327. Matsunuma A, Kawane T, Maeda T, Hamada S, Horiuchi N. Leptin corrects increased gene expression of renal 25- hydroxyvitamin D3-1 alpha-hydroxylase and -24-hydroxylase in leptin-deficient, ob/ob mice. Endocrinology 2004; 145: 1367-75.
328. Niswender KD, Magnuson MA. Obesity and the beta cell: lessons from leptin. J Clin Invest 2007; 117: 2753-6.
329. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-6.
330. Jorde R, Haug E, Figenschau Y, Hansen JB. Serum levels of vitamin D and haemostatic factors in healthy subjects: the Tromso study. Acta Haematol 2007; 117: 91-7.
331. Gannage-Yared MH, Azoury M, Mansour I, Baddoura R, Halaby G, Naaman R. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest 2003; 26: 748-53.
332. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H. Vascular calcification and inorganic phosphate. Am J Kidney Dis 2001; 38: S34-7.
333. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997; 96: 1755-60.
334. Doherty TM, Tang W, Dascalos S, et al. Ethnic origin and serum levels of 1alpha,25-dihydroxyvitamin D3 are independent predic tors of coronary calcium mass measured by electron-beam computed tomography. Circulation 1997; 96: 1477-81
335. Arad Y, Spadaro LA, Roth M, et al. Serum concentration of calcium, 1,25 vitamin D and parathyroid hormone are not correlated with coronary calcifications. An electron beam computed tomography study. Coron Artery Dis 1998; 9: 513-8.
336. Reis JP, von Muhlen D, Michos ED, et al. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis 2009; 207: 585-90.
337. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105-12.
338. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study. Eur J Cardiovasc Prev Rehabil 2004; 11: 69-74.
339. Buell JS, Dawson-Hughes B, Scott TM, et al. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010; 74: 18-26.
340. Zittermann A, Koerfer R. Vitamin D in the prevention and treatment of coronary heart disease. Curr Opin Clin Nutr Metab Care 2008; 11: 752-7.
341. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R. Myocardial infarction is inversely associated with plasma 25- hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 1990; 19: 559-63.
342. Tourlouki E, Polychronopoulos E, Zeimbekis A, et al. The 'secrets' of the long livers in Mediterranean islands: the MEDIS study. Eur J Public Health 2009 Nov 30 [Epub ahead of print].
343. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-11.
344. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730-7.
345. AHA Science News from Scientific Sessions 2009 - Available at http://directnews.americanheart.org/. Last assessed August 10, 2010.
346. LaCroix AZ, Kotchen J, Anderson G, et al. Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci 2009; 64: 559-67.
347. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326: 469.
348. Yavuz B, Ertugrul DT, Cil H, et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 2009; 23: 295-9.
349. Massive vitamin-D/omega-3 trial for CVD, cancer prevention. Available at http://www.theheart.org/article/982711.do. Last assessed August 10, 2010.